Sandip P. Patel, MD, reviews the case of a 60-year-old woman with early-stage non–small cell lung cancer (NSCLC).
Case: A 60-Year-Old Woman with Early-Stage Non–Small Cell Lung Cancer
Initial presentation and Clinical Workup
Treatment
This is a video synopsis/summary of a Case-Based Peer Perspectives featuring Sandip P. Patel, MD.
This case involves a 60-year-old Caucasian female with a 45 pack-year smoking history who presented with a nonproductive cough and was found to have a 5.5-cm right upper lobe lung mass on imaging. Biopsy showed TTF-1–positive adenocarcinoma consistent with non-small cell lung cancer (NSCLC). Staging workup was negative for lymph node involvement or distant metastases. The patient underwent right upper lobectomy with clear margins. Pathology showed a 5.5-cm tumor, pathologic T3N0M0 (stage IIA) lung adenocarcinoma. Molecular testing revealed an EGFR exon 19 deletion and 40% PD-L1 expression.
Postoperatively, the patient completed adjuvant cisplatin and pemetrexed therapy. Due to the EGFR mutation, she was started on osimertinib. Twenty months after initiating osimertinib, she developed headaches and worsening fatigue. Imaging showed 3 new liver lesions concerning for metastases and 1 new potential central nervous system lesion.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Phase 3 CheckMate -73L of Nivolumab/Ipilimumab in NSCLC Misses PFS End Point
May 13th 2024Nivolumab with ipilimumab did not lead to progression-free survival benefits in patients with unresectable stage III non-small cell lung cancer, missing the primary end point of the CheckMate -73L study.
Read More
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More